BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual …

BBO-11818 targets KRAS in both its ON (active GTP-bound) and OFF (inactive GDP-bound) states, potently suppressing MAPK ...

BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma

BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally advanced unresectable or ...

BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026

BBO-10203 physically and allosterically disrupts the interaction between RAS and PI3Kα, leading to signaling inhibition without inhibiting the ...
Targeted Oncology

FDA Grants Fast Track Designation to BBO-11818 in KRAS-Mutant PDAC

FDA fast track designation supports expedited development and regulatory interaction for BBO-11818 in advanced KRAS-mutant ...
Nasdaq

BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and ...

SOUTH SAN FRANCISCO, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway ...
Business Wire

BridgeBio Oncology Therapeutics announces first patient dosed with BBO-8520 in the Ph. 1 ONKORAS-101 trial for KRAS G12C NSCLC

- The first patient has been dosed in the ONKORAS-101 trial for the study of BBO-8520 in adult subjects with KRAS G12C non-small cell lung cancer - BBO-8520 is a first-in-class orally bioavailable and ...
BioWorld

BBOT presents preclinical data on KRAS inhibitor BBO-11818

At the ongoing AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2025 in Boston, Bridgebio Oncology Therapeutics Inc. (BBOT) presented data on BBO-11818, a potent ...
Nasdaq

BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway ...
Seeking Alpha

BBOT BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and ...